Clinical trial
OPTIMAL-DOSE: A Randomized, Open-Label, Non-Inferiority Trial Comparing Fixed Daily Doses of 150 IU Versus 225 IU of Follicle-Stimulating Hormone in Predicted Normal Responders Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection
NCT07346235 is registered in ClinicalTrials.gov with American Hospital 2 Kosovo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OPTIMAL-DOSE: A Randomized, Open-Label, Non-Inferiority Trial Comparing Fixed Daily Doses of 150 IU Versus 225 IU of Follicle-Stimulating Hormone in Predicted Normal Responders Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection
- Lead sponsor
- American Hospital 2 Kosovo
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- January 15, 2029
- Enrollment
- 440 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.